Abstract
Purpose
Renal cell carcinoma (RCC) incidence has considerably increased during the last decades without any real impact on age-standardized mortality. It questions the relevance of aggressive treatments carrying potential side effects. Conservative management should be considered for frail patients. Comorbidity and frailty assessment in RCC patients is paramount before engaging a treatment.
Methods
Narrative, non-systematic review based on PubMed and EMBASE search with the terms “renal neoplasm”, “elderly, frail”, “comorbidities”, “active surveillance”, “metastatic”. The selection was restricted to articles written in English.
Results
Comorbidity and frailty assessment go along with the cancer-specific aggressivity and intervention risks assessment. In localized disease, several standardized algorithms offer patient health evaluation to define how suitable the patient would be for curative treatment. The pre-operative American Society of Anesthesiologists and the age-adjusted Charlson’s scores are the most widely used. At the metastatic stage, drug combinations based on immunotherapies and targeted therapies improved cancer outcomes at the price of significant toxicities. Frail patients are not always suitable for such strategies. Commonly used scores like the International Metastatic RCC Database Consortium or Memorial Sloan Kettering Cancer Center integrate features to define patients’ risk groups, more specifically the Karnofsky Performance Score is an easy way to document the frailty.
Conclusions
Comorbidity and frailty have to be assessed at any stage of the RCC disease based on a standardized scoring system to define the most suitable treatment strategy ranging from surveillance to aggressive treatment.
Similar content being viewed by others
References
Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Weikert S, Ljungberg B (2010) Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. World J Urol 28:247–252. https://doi.org/10.1007/s00345-010-0555-1
Padala SA, Barsouk A, Thandra KC et al (2020) Epidemiology of renal cell carcinoma. World J Oncol 11:79–87. https://doi.org/10.14740/wjon1279
SEER*Explorer Application. https://seer.cancer.gov/explorer/application.html?site=630&data_type=4&graph_type=5&compareBy=sex&chk_sex_1=1&series=9&race=1&age_range=1&stage=101&advopt_precision=1#tableWrap. Accessed 9 Jan 2021
Vermooten V (1950) Indications for conservative surgery in certain renal tumors: a study based on the growth pattern of the cell carcinoma. J Urol 64:200–208. https://doi.org/10.1016/s0022-5347(17)68620-8
Jewett MAS, Mattar K, Basiuk J et al (2011) Active surveillance of small renal masses: progression patterns of early stage kidney cancer. EurUrol 60:39–44. https://doi.org/10.1016/j.eururo.2011.03.030
Curigliano G (2020) Recent eUpdate on cabozantinib and nivolumab for first-line clear cell renal cancer to the ESMO Clinical Practice Guidelines on Renal Cell Carcinoma. Ann Oncol. https://doi.org/10.1016/j.annonc.2020.11.016
Rini BI, Powles T, Atkins MB et al (2019) Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393:2404–2415. https://doi.org/10.1016/S0140-6736(19)30723-8
Powles T, Plimack ER, Soulières D et al (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30436-8
Choueiri TK, Motzer RJ, Rini BI et al (2020) Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 31:1030–1039. https://doi.org/10.1016/j.annonc.2020.04.010
Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290. https://doi.org/10.1056/NEJMoa1712126
Ljungberg B, Albiges L, Abu-Ghanem Y et al (2019) European Association of Urology Guidelines on Renal Cell Carcinoma: the 2019 update. EurUrol 75:799–810. https://doi.org/10.1016/j.eururo.2019.02.011
Chawla SN, Crispen PL, Hanlon AL et al (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175:425–431. https://doi.org/10.1016/S0022-5347(05)00148-5
Frank I, Blute ML, Cheville JC et al (2003) Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 170:2217–2220. https://doi.org/10.1097/01.ju.0000095475.12515.5e
Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98:1331–1334. https://doi.org/10.1093/jnci/djj362
Lane BR, Abouassaly R, Gao T et al (2010) Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 116:3119–3126. https://doi.org/10.1002/cncr.25184
Smaldone MC, Kutikov A, Egleston BL et al (2012) Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 118:997–1006. https://doi.org/10.1002/cncr.26369
Finelli A, Cheung DC, Al-Matar A et al (2020) Small renal mass surveillance: histology-specific growth rates in a biopsy-characterized cohort. EurUrol 78:460–467. https://doi.org/10.1016/j.eururo.2020.06.053
Mehrazin R, Smaldone MC, Kutikov A et al (2014) Growth kinetics and short-term outcomes of cT1b and cT2 renal masses under active surveillance. J Urol 192:659–664. https://doi.org/10.1016/j.juro.2014.03.038
Cheung DC, Finelli A (2017) Active surveillance in small renal masses in the elderly: a literature review. EurUrol Focus 3:340–351. https://doi.org/10.1016/j.euf.2017.11.005
Lowrance WT, Yee DS, Savage C et al (2010) Complications after radical and partial nephrectomy as a function of age. J Urol 183:1725–1730. https://doi.org/10.1016/j.juro.2009.12.101
Sirithanaphol W, Pachirat K, Rompsaithong U et al (2019) Perioperative outcomes in elderly patients undergoing nephrectomy for renal cell carcinoma. Res Rep Urol 11:195–199. https://doi.org/10.2147/RRU.S220221
ASA Physical Status Classification System. https://www.asahq.org/standards-and-guidelines/asa-physical-status-classification-system. Accessed 3 Nov 2020
Mir MC, Derweesh I, Porpiglia F et al (2017) Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. EurUrol 71:606–617. https://doi.org/10.1016/j.eururo.2016.08.060
Van Poppel H, Da Pozzo L, Albrecht W et al (2007) A prospective randomized EORTC Intergroup Phase 3 Study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. EurUrol 51:1606–1615. https://doi.org/10.1016/j.eururo.2006.11.013
Becker A, Ravi P, Roghmann F et al (2014) Laparoscopic radical nephrectomy vs laparoscopic or open partial nephrectomy for T1 renal cell carcinoma: comparison of complication rates in elderly patients during the initial phase of adoption. Urology 83:1285–1293. https://doi.org/10.1016/j.urology.2014.01.050
Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J GerontolABiolSci Med Sci 56:M146-156. https://doi.org/10.1093/gerona/56.3.m146
Hidayat K, Du X, Zou S-Y, Shi B-M (2017) Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens 35:1333–1344. https://doi.org/10.1097/HJH.0000000000001286
Tahbaz R, Schmid M, Merseburger AS (2018) Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. CurrOpinUrol 28:62–79. https://doi.org/10.1097/MOU.0000000000000454
Al-Bayati O, Hasan A, Pruthi D et al (2019) Systematic review of modifiable risk factors for kidney cancer. UrolOncol 37:359–371. https://doi.org/10.1016/j.urolonc.2018.12.008
Xu X, Zhu Y, Zheng X, Xie L (2015) Does beer, wine or liquor consumption correlate with the risk of renal cell carcinoma? A dose-response meta-analysis of prospective cohort studies. Oncotarget 6:13347–13358. https://doi.org/10.18632/oncotarget.3749
Choueiri TK, Je Y, Cho E (2014) Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies. Int J Cancer 134:384–396. https://doi.org/10.1002/ijc.28093
Capitanio U, Bensalah K, Bex A et al (2019) Epidemiology of renal cell carcinoma. EurUrol 75:74–84. https://doi.org/10.1016/j.eururo.2018.08.036
Fried LP, Borhani NO, Enright P et al (1991) The cardiovascular health study: design and rationale. Ann Epidemiol 1:263–276. https://doi.org/10.1016/1047-2797(91)90005-W
Bellera CA, Rainfray M, Mathoulin-Pélissier S et al (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23:2166–2172. https://doi.org/10.1093/annonc/mdr587
Wildiers H, Heeren P, Puts M et al (2014) International Society of Geriatric Oncology Consensus on geriatric assessment in older patients with cancer. J ClinOncol 32:2595–2603. https://doi.org/10.1200/JCO.2013.54.8347
Kenis C, Decoster L, Van Puyvelde K et al (2014) Performance of two geriatric screening tools in older patients with cancer. J ClinOncol 32:19–26. https://doi.org/10.1200/JCO.2013.51.1345
Soubeyran P, Bellera C, Goyard J et al (2014) Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS One 9:e115060. https://doi.org/10.1371/journal.pone.0115060
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8
Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J ClinEpidemiol 47:1245–1251. https://doi.org/10.1016/0895-4356(94)90129-5
The KORCC (KOrean Renal Cell Carcinoma) Group, Kang HW, Kim SM et al (2020) The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma. J Cancer Res ClinOncol 146:187–196. https://doi.org/10.1007/s00432-019-03042-7
Kutikov A, Egleston BL, Wong Y-N, Uzzo RG (2010) Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J ClinOncol Off J Am SocClinOncol 28:311–317. https://doi.org/10.1200/JCO.2009.22.4816
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899. https://doi.org/10.1016/j.cell.2010.01.025
Hu X, Wang Y, Yang W-X et al (2019) Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis. Cancer Manag Res 11:6163–6173. https://doi.org/10.2147/CMAR.S208839
Escudier B, Porta C, Schmidinger M et al (2016) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann OncolOff J EurSoc Med Oncol 27:v58–v68. https://doi.org/10.1093/annonc/mdw328
Rini BI, Dorff TB, Elson P et al (2016) Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol 17:1317–1324. https://doi.org/10.1016/S1470-2045(16)30196-6
Wong AS, Chong K-T, Heng C-T et al (2009) Debulking nephrectomy followed by a “watch and wait” approach in metastatic renal cell carcinoma. UrolOncol 27:149–154. https://doi.org/10.1016/j.urolonc.2007.10.017
Kushnir I, Basappa NS, Ghosh S et al (2019) Active surveillance in metastatic renal cell carcinoma (mRCC): results from the Canadian Kidney Cancer information system (CKCis). J ClinOncol 37:4516–4516. https://doi.org/10.1200/JCO.2019.37.15_suppl.4516
Ficarra V, Mosca A, Rossanese M et al (2019) Is active surveillance an option for metachronous metastatic renal cell carcinoma? Ann Transl Med 7:84. https://doi.org/10.21037/atm.2019.01.08
Bimbatti D, Ciccarese C, Fantinel E et al (2018) Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. UrolOncolSeminOrigInvestig 36:526.e13-526.e18. https://doi.org/10.1016/j.urolonc.2018.08.018
Albiges L, Powles T, Staehler M et al (2019) Updated European Association of Urology Guidelines on Renal Cell Carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. EurUrol 76:151–156. https://doi.org/10.1016/j.eururo.2019.05.022
Capitanio U, Larcher A, Dell’Oglio P, Montorsi F (2017) Re: Brian I. Rini, Tanya B. Dorff, Paul Elson, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol Lancet 2016;17:1317-24: Active surveillance in metastatic renal cell carcinoma: option or exception? EurUrol 71:e139–e140. https://doi.org/10.1016/j.eururo.2016.09.034
Ljungberg B, Bensalah K, Canfield S et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. EurUrol 67:913–924. https://doi.org/10.1016/j.eururo.2015.01.005
Choueiri TK, Powles T, Burotto M, Bourlon MT, Zurawski B, Juárez VMO, Hsieh JJ, Basso U, Shah AY, Suarez C, Hamzaj A, Barrios CH, Richardet M, Pook D, Tomita Y, Escudier B, Zhang J, Simsek B, Apolo AB, Motzer RJ (2020) Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. Ann Oncol 31(Suppl4):S1142–S1215. https://doi.org/10.1016/annoncannonc325
Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116–1127. https://doi.org/10.1056/NEJMoa1816714
Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103–1115. https://doi.org/10.1056/NEJMoa1816047
Rini BI, Powles T, Atkins MB et al (2019) Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet LondEngl 393:2404–2415. https://doi.org/10.1016/S0140-6736(19)30723-8
Bhojani N, Jeldres C, Patard J-J et al (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. EurUrol 53:917–930. https://doi.org/10.1016/j.eururo.2007.11.037
Manz KM, Fenchel K, Eilers A et al (2020) Efficacy and safety of approved first-line tyrosine kinase inhibitor treatments in metastatic renal cell carcinoma: a network meta-analysis. AdvTher 37:730–744. https://doi.org/10.1007/s12325-019-01167-2
Thompson JA (2018) New NCCN Guidelines: recognition and management of immunotherapy-related toxicity. J NatlCompr Cancer Netw JNCCN 16:594–596. https://doi.org/10.6004/jnccn.2018.0047
Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168. https://doi.org/10.1056/NEJMra1703481
Shoushtari AN, Friedman CF, Navid-Azarbaijani P et al (2018) Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol 4:98–101. https://doi.org/10.1001/jamaoncol.2017.2391
Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356. https://doi.org/10.1056/NEJMoa1709684
Bertrand A, Kostine M, Barnetche T et al (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13:211. https://doi.org/10.1186/s12916-015-0455-8
Wang Y, Zhou S, Yang F et al (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 5:1008–1019. https://doi.org/10.1001/jamaoncol.2019.0393
Wang DY, Salem J-E, Cohen JV et al (2018) Fatal Toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721–1728. https://doi.org/10.1001/jamaoncol.2018.3923
Kennedy LB, Salama AKS (2020) A review of cancer immunotherapy toxicity. CA Cancer J Clin 70:86–104. https://doi.org/10.3322/caac.21596
Esther J, Hale P, Hahn AW et al (2019) Treatment decisions for metastatic clear cell renal cell carcinoma in older patients: the role of TKIs and immune checkpoint inhibitors. Drugs Aging 36:395–401. https://doi.org/10.1007/s40266-019-00644-1
Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J ClinOncol Off J Am SocClinOncol 20:289–296. https://doi.org/10.1200/JCO.2002.20.1.289
Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J ClinOncol Off J Am SocClinOncol 17:2530–2540. https://doi.org/10.1200/JCO.1999.17.8.2530
Heng DYC, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J ClinOncol Off J Am SocClinOncol 27:5794–5799. https://doi.org/10.1200/JCO.2008.21.4809
Heng DYC, Xie W, Regan MM et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141–148. https://doi.org/10.1016/S1470-2045(12)70559-4
Yip S, Wells C, Moreira RB et al (2017) Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC. J ClinOncol 35:492–492. https://doi.org/10.1200/JCO.2017.35.6_suppl.492
Pal SK, Ghate SR, Li N et al (2017) Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: a SEER–Medicare Database analysis. ClinGenitourin Cancer 15:e573–e582. https://doi.org/10.1016/j.clgc.2016.12.005
Pal S, Gong J, Mhatre SK et al (2019) Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer 19:548. https://doi.org/10.1186/s12885-019-5716-z
Buccheri G, Ferrigno D (1990) Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer OxfEngl 32A:1135–1141. https://doi.org/10.1016/0959-8049(95)00664-8
Yancik R, Ganz PA, Varricchio CG, Conley B (2001) Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J ClinOncolOff J Am SocClinOncol 19:1147–1151. https://doi.org/10.1200/JCO.2001.19.4.1147
Donskov F, Motzer RJ, Voog E et al (1990) (2020) Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. Eur J Cancer OxfEngl 126:1–10. https://doi.org/10.1016/j.ejca.2019.10.032
Funding
None.
Author information
Authors and Affiliations
Contributions
J Courcier: manuscript writing; A De La Taille: manuscript editing; N Lassau: manuscript editing; A Ingels: project development, manuscript writing/editing.
Corresponding author
Ethics declarations
Conflict of interest
Jean COURCIER None. Alexandre DE LA TAILLE Intuitive Surgical. Nathalie LASSAU Jazz Pharmaceuticals. Alexandre INGELS Intuitive Surgical, Bristol-Myers Squibb.
Research involving human participants and/or animals
None.
Informed consent
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Courcier, J., De La Taille, A., Lassau, N. et al. Comorbidity and frailty assessment in renal cell carcinoma patients. World J Urol 39, 2831–2841 (2021). https://doi.org/10.1007/s00345-021-03632-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-021-03632-6